Literature DB >> 32194173

Nanoparticle depots for controlled and sustained gene delivery.

Zhongyu Li1, William Ho1, Xin Bai2, Fengqiao Li1, Yen-Jui Chen1, Xue-Qing Zhang3, Xiaoyang Xu4.   

Abstract

Gene therapy is one of the most promising medical fields which holds the potential to rapidly advance the treatment of difficult ailments such as cancer as well as inherited genetic diseases. However, clinical translation is limited by several drug delivery hurdles including renal clearance, phagocytosis, enzymatic degradation, protein absorption, as well as cellular internalization barriers. Additionally, successful treatments require sustained release of drug payloads to maintain the effective therapeutic level. As such, controlled and sustained release is a significant concern as the localization and kinetics of nucleic acid therapeutics can significantly influence the therapeutic efficacy. This is an unmet need which calls for the development of controlled-release nanoparticle (NP) technologies to further improve the gene therapy efficacy by prolonging the release of nucleic acid drug payload for sustained, long-term gene expression or silencing. Herein, we present a polymeric NP system with sustained gene delivery properties, which can be synthesized using biodegradable and biocompatible polymers via self-assembly. The NP delivery system is composed of a polymeric NP which acts as a drug depot encapsulating cationic polymer/nucleic acid complexes, facilitating the enhanced retention and prolonged release of the gene payload. The NPs showed excellent cellular biocompatibility and gene delivery efficacy using the green fluorescent protein (GFP) encoded DNA plasmid (pGFP) as a reporter gene. Sustained release of the pGFP payload was shown over a period of 8 days. The physicochemical properties such as morphology, particle size, zeta potential, pGFP encapsulation efficiency and biological properties such as pGFP release profile, in vitro cytotoxicity and transfection efficacy in Hek 293 cells were characterized and evaluated. Importantly, the NP-mediated sustained release of pGFP generates enhanced GFP expression over time. We expect this NP-mediated gene delivery system to provide safe and sustained release of various nucleic acid-based therapeutics with applications in both fundamental biological studies and clinical translations.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Gene therapy; Nanoparticles; Sustained release

Mesh:

Year:  2020        PMID: 32194173     DOI: 10.1016/j.jconrel.2020.03.021

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  4 in total

Review 1.  Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components.

Authors:  Pardis Kazemian; Si-Yue Yu; Sarah B Thomson; Alexandra Birkenshaw; Blair R Leavitt; Colin J D Ross
Journal:  Mol Pharm       Date:  2022-05-20       Impact factor: 5.364

Review 2.  Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery.

Authors:  William Ho; Mingzhu Gao; Fengqiao Li; Zhongyu Li; Xue-Qing Zhang; Xiaoyang Xu
Journal:  Adv Healthc Mater       Date:  2021-01-18       Impact factor: 11.092

3.  Light-controllable charge-reversal nanoparticles with polyinosinic-polycytidylic acid for enhancing immunotherapy of triple negative breast cancer.

Authors:  Lei Fang; Zitong Zhao; Jue Wang; Ping Xiao; Xiangshi Sun; Yaping Ding; Pengcheng Zhang; Dangge Wang; Yaping Li
Journal:  Acta Pharm Sin B       Date:  2021-06-15       Impact factor: 11.413

4.  Lipid-Polymer Hybrid "Particle-in-Particle" Nanostructure Gene Delivery Platform Explored for Lyophilizable DNA and mRNA COVID-19 Vaccines.

Authors:  Zhongyu Li; Xue-Qing Zhang; William Ho; Xin Bai; Dabbu Kumar Jaijyan; Fengqiao Li; Ranjeet Kumar; Afsal Kolloli; Selvakumar Subbian; Hua Zhu; Xiaoyang Xu
Journal:  Adv Funct Mater       Date:  2022-07-22       Impact factor: 19.924

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.